Connect Biopharma Holdings Limited (CNTB)
Market Cap | 76.04M |
Revenue (ttm) | n/a |
Net Income (ttm) | -59.50M |
Shares Out | 55.10M |
EPS (ttm) | -0.15 |
PE Ratio | n/a |
Forward PE | 1.87 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 18,559 |
Open | 1.550 |
Previous Close | 1.440 |
Day's Range | 1.350 - 1.550 |
52-Week Range | 0.535 - 2.840 |
Beta | -0.35 |
Analysts | Strong Buy |
Price Target | 6.50 (+371.01%) |
Earnings Date | Apr 16, 2024 |
About CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory dis... [Read more]
Analyst Forecast
According to 2 analysts, the average rating for CNTB stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 371.01% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/3/l/press5-2504512.jpg)
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceu...
![](https://cdn.snapi.dev/images/v1/o/4/press12-2476790.jpg)
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceu...
![](https://cdn.snapi.dev/images/v1/m/i/press3-2476630.jpg)
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceu...
![](https://cdn.snapi.dev/images/v1/c/d/press1-2444283.jpg)
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical c...
![](https://cdn.snapi.dev/images/v1/d/u/conf13-2414066.jpg)
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical c...
![](https://cdn.snapi.dev/images/v1/w/h/press1-2374522.jpg)
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
SAN DIEGO, CA and TAICANG, China, April 16, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a global clinical-stage biopha...
![](https://cdn.snapi.dev/images/v1/c/n/conf5-2330832.jpg)
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical com...
![](https://cdn.snapi.dev/images/v1/j/p/press14-2272356.jpg)
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/s/i/press3-2192393.jpg)
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/p/3/conf5-2191827.jpg)
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/h/p/press6-2166638.jpg)
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/w/9/press17-2166631.jpg)
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/q/y/conf8-2166146.jpg)
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/j/i/press16-2060485.jpg)
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical com...
![](https://cdn.snapi.dev/images/v1/y/g/press9-2058917.jpg)
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical com...
![](https://cdn.snapi.dev/images/v1/n/u/conf13-2037028.jpg)
Connect Biopharma to Participate in Upcoming September Investor Conferences
SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical comp...
![](https://cdn.snapi.dev/images/v1/i/y/press17-1963978.jpg)
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
SAN DIEGO and TAICANG, China, July 10, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical comp...
![](https://cdn.snapi.dev/images/v1/z/v/press16-1959502.jpg)
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
SAN DIEGO and TAICANG, China, July 05, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical comp...
![](https://cdn.snapi.dev/images/v1/j/e/press17-1917511.jpg)
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
SAN DIEGO, CA and TAICANG, China, June 01, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/m/q/press9-1833218.jpg)
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
CDE's Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track for NDA Submission in China by End of First Quarter 2024
![](https://cdn.snapi.dev/images/v1/b/7/press13-1803117.jpg)
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
SAN DIEGO & TAICANG, China & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company dev...
![](https://cdn.snapi.dev/images/v1/b/b/connect-biopharma-0112-1185084-1802721.jpeg)
Connect Biopharma stock up more than 40% after trial data
Connect Biopharma Holdings Ltd. CNTB, -3.51% stock rose more than 40% in the extended session Friday after the company said that analysis of a trial involving one of its therapies to treat moderate-to...
![](https://cdn.snapi.dev/images/v1/u/8/press1-1802674.jpg)
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
SAN DIEGO & TAICANG, China & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company dev...
![](https://cdn.snapi.dev/images/v1/s/o/press9-1783442.jpg)
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO & TAICANG & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing...
![](https://cdn.snapi.dev/images/v1/x/l/conf8-1739896.jpg)
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven th...